What is the dose of intramuscular (IM) adrenaline for anaphylaxis treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Dosing of IM Adrenaline (Epinephrine) for Anaphylaxis Treatment

The recommended dose of intramuscular (IM) adrenaline for anaphylaxis treatment is 0.01 mg/kg of 1:1000 concentration (1 mg/mL), up to a maximum of 0.5 mg for adults and 0.3 mg for children, administered in the anterolateral thigh (vastus lateralis muscle). 1, 2

Adult Dosing

  • Adults and children weighing ≥30 kg (66 lbs): 0.3-0.5 mg (0.3-0.5 mL) of undiluted 1:1000 adrenaline administered intramuscularly 2
  • Maximum single dose: 0.5 mg per injection 1, 2
  • Dose may be repeated every 5-10 minutes as necessary based on clinical response 2

Pediatric Dosing

  • Children <30 kg (66 lbs): 0.01 mg/kg (0.01 mL/kg) of undiluted 1:1000 adrenaline administered intramuscularly 2
  • Maximum single dose: 0.3 mg per injection 2
  • For autoinjectors in children:
    • 0.15 mg dose for children weighing 10-25 kg (22-55 lbs) 1
    • 0.3 mg dose for children weighing ≥25 kg (55 lbs) 1
  • Dose may be repeated every 5-10 minutes as necessary based on clinical response 2

Administration Technique

  • Inject into the anterolateral aspect of the thigh (vastus lateralis muscle) 1, 2
  • Can be administered through clothing if necessary in emergency situations 2
  • When administering to children, hold the leg firmly in place to minimize risk of injection-related injury 2
  • Do not administer repeated injections at the same site due to risk of tissue necrosis from vasoconstriction 2

Important Clinical Considerations

  • Intramuscular injection in the lateral thigh leads to faster absorption compared to subcutaneous injection (peak plasma concentration at 8±2 minutes vs. 34±14 minutes) 1
  • No absolute contraindications exist for using epinephrine to treat anaphylaxis, even in patients with cardiac disease, advanced age, or frailty 1
  • Monitor the patient clinically for severity of allergic reaction and potential cardiac effects 2
  • Delay in administering epinephrine has been associated with anaphylaxis fatalities and increased risk of biphasic reactions 1

Special Situations

  • For severe, refractory anaphylaxis unresponsive to IM epinephrine, IV epinephrine infusion may be considered at 1-4 mcg/min, titrated up to a maximum of 10 mcg/min 3
  • Biphasic reactions (recurrence of symptoms after initial resolution) may occur up to 72 hours later, with a mean of 11 hours 1
  • Patients requiring more than one dose of epinephrine have higher risk of biphasic reactions 1

Common Pitfalls to Avoid

  • Delaying epinephrine administration while giving antihistamines or corticosteroids first - epinephrine is the first-line treatment 1, 4
  • Using subcutaneous instead of intramuscular route, which delays absorption 1
  • Administering intravenous epinephrine outside of hospital settings or without appropriate monitoring, which increases risk of serious adverse effects 1
  • Underdosing in adults or overdosing in small children due to fixed-dose autoinjectors 1
  • Failure to repeat dose if symptoms persist 2, 4

Remember that epinephrine is the cornerstone of anaphylaxis management and should be administered promptly, as delays may be fatal 4. The intramuscular route in the lateral thigh is preferred for first-aid treatment of anaphylaxis 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Epinephrine Drip Dosing for Severe Allergic Reactions/Anaphylaxis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The role of epinephrine in the treatment of anaphylaxis.

Current allergy and asthma reports, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.